GeneDx Holdings Corp. Class A (WGS)
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
WGS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.36B
- Forward P/E
- 34.93
- EPS (TTM)
- -$3.76
- Dividend yield
- None
- 52-week range
- 32.21 – 170.87
- Day range
- 45.16 – 49.10
- Volume / Avg
- 912.39K / 869.34K
- Beta
- —
- Shares outstanding
- 29.97M
52-week range
WGS stock today
GeneDx (WGS) closed at $45.46 on Nov 20, down 7.68% (-$3.78), versus the S&P 500's 3.70% decline. Shares are 73.4% below their 52-week high of $170.87, set on Dec 2, 2025 and 41.1% above the 52-week low of $32.21, near the bottom of the past year's range. WGS is down 65.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 69.0%.
GeneDx has posted a net loss over the last twelve months (EPS of -$3.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About GeneDx
Company profileGeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- CEO
- Ms. Katherine A. Stueland
- Headquarters
- Stamford, CT
- Employees
- 1,300
- IPO year
- 2020
- Website
- genedx.com
Financial highlights
Full financialsIn fiscal 2025, GeneDx generated $427.5 million in revenue, up 40.0% from fiscal 2024, its 2nd consecutive year of revenue growth. GeneDx reported a net loss of $21.0 million, compared with a loss of $52.3 million a year earlier. Gross margin was 69.7% (up from 63.6%) and operating margin -3.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $427.54M | $305.45M | $202.57M | $234.69M | $212.19M |
| Growth | +39.97% | +50.79% | -13.69% | +10.60% | +18.33% |
| Net income | $-21.02M | $-52.29M | $-175.77M | $-548.98M | $-245.39M |
| EPS (diluted) | $-0.73 | $-1.94 | $-7.23 | $-53.63 | $-2.27 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$82.00+80.38%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $0.49 vs $0.07
- Surprise
- +600.00%
WGS news
All WGS news- GeneDx Holdings Corp. Appoints Everett Cunningham as CEO, Succeeding Katherine StuelandNasdaq
- GeneDx names new CEOSeeking Alpha
- Why GeneDx Holdings Stock Just Dropped 16.6%Nasdaq
- GeneDx falls as Q4 outlook misses consensusSeeking Alpha
- GeneDx (WGS) Q3 2026 Earnings Call TranscriptNasdaq
- Genedx outlines Q4 revenue of at least $135M while raising 2026 adjusted net income guidance to at least $12MSeeking Alpha
- GeneDx Holdings Corp. Reports Third Quarter 2026 Financial ResultsNasdaq
- GeneDx Holdings GAAP EPS of -$0.41 misses by $0.03, revenue of $123.1M beats by $0.18MSeeking Alpha
GeneDx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TDOCTeladoc Health Inc. | 7.45 | -4.36% | $1.36B | vs WGS |
| USPHU.S. Physical Therapy Inc. | 95.93 | +1.71% | $1.43B | vs WGS |
| INNVInnovAge Holding Corp. | 9.16 | +2.81% | $1.25B | vs WGS |
| PNTGThe Pennant Group Inc. | 34.64 | +1.61% | $1.22B | vs WGS |
| AHCOAdaptHealth Corp. | 7.20 | -0.69% | $982.98M | vs WGS |
| OMDAOmada Health Inc. | 11.87 | -5.04% | $736.39M | vs WGS |
| SBCSBC Medical Group Holdings Incorporated | 5.17 | -7.68% | $530.32M | vs WGS |
| ADUSAddus HomeCare Corporation | 122.50 | +1.18% | $2.28B | vs WGS |
Indexes, lists and sector
GeneDx stock FAQ
What is GeneDx's stock price today?
WGS last traded at $45.46 as of Nov 20, 4:00 PM EST, down 7.68% on the day. Prices are delayed at least 15 minutes.
Does GeneDx pay a dividend?
No. GeneDx does not currently pay a regular cash dividend.
Who is GeneDx's CEO?
Ms. Katherine A. Stueland is the chief executive officer of GeneDx Holdings Corp. Class A, which has about 1,300 employees.
Has WGS ever split its stock?
Yes. The most recent WGS stock split was a 1-for-33 split on May 4, 2023.
What is the WGS 52-week high?
The 52-week high for WGS is $170.87 and the 52-week low is $32.21. The stock is currently 73.4% below its high.